On January 26, 2021 EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, reported the appointment of Dr Hilary McElwaine-Johnn as Chief Medical Officer (Press release, Exact Therapeutics, JAN 26, 2021, View Source [SID1234578277]). Dr McElwaine-Johnn will be based at the newly opened London office of EXACT-Tx at the Translation & Innovation Hub (i-Hub) at White City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to welcome Hilary to EXACT Therapeutics AS where her unique experience in both therapeutics and drug delivery complemented by deep medical expertise will be pivotal in driving forward the development of ACT, both in the ongoing Phase I ACTIVATE study and beyond",
said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.
"Hilary joins EXACT-Tx at an exciting time as we expand our presence in the UK with the opening of our London office at the White City i-Hub in close proximity to the growing Imperial College campus".
Dr McElwaine-Johnn gained her medical degree from Imperial College, London and is a Member of the Royal College of Physicians and Faculty of Pharmaceutical Medicine. Following clinical roles in general internal medicine and oncology, she has pursued a highly successful career in the pharmaceutical industry. She has held a variety of senior medical positions including Vice President, Clinical, PowderMed Ltd (which was subsequently acquired by Pfizer), Chief Medical Officer of Vantia Ltd, PsiOxus Therapeutics Ltd and most recently Karus Therapeutics. During this time Hilary has gained extensive experience in drug development in both oncology and other therapeutic indications as well as delivery technologies complemented by a range of successful interactions with Regulatory Authorities, partner companies and fundraising activities.
Dr McElwaine-Johnn commented:
"I am excited to be joining EXACT Therapeutics in London to be part of a dynamic and innovative organization exploring the potential of the ACT platform to transform clinical practice across indications, particularly in the management of patients with cancer. With a strong preclinical evidence base and clinical development of ACT already underway, I am looking forward to working with the clinical community in further investigating this exciting approach to ultrasound mediated therapeutic targeting."
About ACT
• ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the company is oncology, however the ACT platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.